Halozyme Therapeutics Inc. Common Stock (HALO) fair value

ACCE thesis

Halozyme licenses its ENHANZE hyaluronidase enzyme platform, which lets large-molecule drugs such as Keytruda and Opdivo be delivered by subcutaneous injection in minutes instead of by lengthy intravenous infusion, and it collects royalties and milestones on each partner's sales. The moat is the platform itself: partners such as Merck and BMS build their subcutaneous franchises on Halozyme's technology, which makes the royalty stream sticky and hard to displace. The near-term driver is the rollout of subcutaneous versions of blockbuster antibodies as more patents and approvals arrive, with each new partner product adding a royalty line. The stock trades at 35.6 times trailing earnings but only 11.4 times forward, and revenue grew 47.7% with a 59.8% operating margin, so the market is pricing in a steep earnings step-up that the next few reporting periods will either confirm or question. The company is outside the major indices, which makes it a candidate for a closer look at what the forward numbers actually require.